MX348290B - Formas cristalinas de un inhibidor de tirosina quinasa de bruton. - Google Patents

Formas cristalinas de un inhibidor de tirosina quinasa de bruton.

Info

Publication number
MX348290B
MX348290B MX2014014848A MX2014014848A MX348290B MX 348290 B MX348290 B MX 348290B MX 2014014848 A MX2014014848 A MX 2014014848A MX 2014014848 A MX2014014848 A MX 2014014848A MX 348290 B MX348290 B MX 348290B
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
crystalline forms
bruton
inhibitor
kinase inhibitor
Prior art date
Application number
MX2014014848A
Other languages
English (en)
Other versions
MX2014014848A (es
Inventor
Smyth Mark
Goldman Erick
D Wirth David
Purro Norbert
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX348290(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2014014848A publication Critical patent/MX2014014848A/es
Publication of MX348290B publication Critical patent/MX348290B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)

Abstract

La presente invención se refiere al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo [3,4-d] pirimidin-1-il) piperidin-1-il) prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias.
MX2014014848A 2012-06-04 2013-06-03 Formas cristalinas de un inhibidor de tirosina quinasa de bruton. MX348290B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261655381P 2012-06-04 2012-06-04
PCT/US2013/043888 WO2013184572A1 (en) 2012-06-04 2013-06-03 Crystalline forms of a bruton's tyrosine kinase inhibitor

Publications (2)

Publication Number Publication Date
MX2014014848A MX2014014848A (es) 2015-07-06
MX348290B true MX348290B (es) 2017-06-05

Family

ID=49712527

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014014848A MX348290B (es) 2012-06-04 2013-06-03 Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
MX2017006815A MX387669B (es) 2012-06-04 2013-06-03 Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
MX2021012478A MX2021012478A (es) 2012-06-04 2014-12-04 Formas cristalinas de un inhibidor de tirosina quinasa de bruton.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2017006815A MX387669B (es) 2012-06-04 2013-06-03 Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
MX2021012478A MX2021012478A (es) 2012-06-04 2014-12-04 Formas cristalinas de un inhibidor de tirosina quinasa de bruton.

Country Status (32)

Country Link
US (27) US9296753B2 (es)
EP (1) EP2854859B1 (es)
JP (10) JP6236071B2 (es)
KR (8) KR20250151610A (es)
CN (2) CN110354132A (es)
AR (2) AR092844A1 (es)
AU (7) AU2013271918C1 (es)
BR (1) BR112014030424A8 (es)
CA (4) CA3218491A1 (es)
CL (3) CL2014003306A1 (es)
CO (1) CO7240408A2 (es)
CR (1) CR20140558A (es)
DO (3) DOP2014000274A (es)
EA (1) EA201492082A1 (es)
EC (2) ECSP14033163A (es)
GT (1) GT201400281A (es)
HK (1) HK1208803A1 (es)
IL (4) IL315394A (es)
JO (2) JO3754B1 (es)
MA (2) MA37711A1 (es)
MX (3) MX348290B (es)
MY (2) MY194911A (es)
NZ (4) NZ731932A (es)
PE (3) PE20241581A1 (es)
PH (3) PH12021552282A1 (es)
SG (2) SG11201408067YA (es)
TN (1) TN2014000492A1 (es)
TW (3) TWI662963B (es)
UA (2) UA126959C2 (es)
UY (2) UY39740A (es)
WO (1) WO2013184572A1 (es)
ZA (4) ZA202105175B (es)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
CN105362277A (zh) 2008-07-16 2016-03-02 药品循环有限公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
AU2012205601B2 (en) 2011-01-11 2016-03-24 Novartis Ag Combination
BR112014000653A2 (pt) 2011-07-13 2017-02-14 Pharmacyclics Inc inibidores de tirosina quinase de bruton
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
EP2788343B1 (en) 2011-12-11 2018-02-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EA201492082A1 (ru) * 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
PE20151604A1 (es) * 2012-11-02 2015-11-04 Pharmacyclics Llc Terapia adyuvante con inhibidores de quinasa de la familia tec
MX2015006168A (es) 2012-11-15 2015-08-10 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas.
RU2693480C2 (ru) 2013-03-14 2019-07-03 Толеро Фармасьютикалз, Инк. Ингибиторы jak2 и alk2 и способы их использования
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
ES2709509T3 (es) 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
KR20230047203A (ko) 2013-08-22 2023-04-06 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
KR20160062103A (ko) 2013-09-30 2016-06-01 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
WO2015054612A1 (en) * 2013-10-11 2015-04-16 University Of Massachusetts Treating organ-specific t cell mediated autoimmune diseases
EP3060218A4 (en) 2013-10-25 2017-07-19 Pharmacyclics LLC Methods of treating and preventing graft versus host disease
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
US10272083B2 (en) * 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
CN105949197A (zh) * 2014-01-29 2016-09-21 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
KR20160127754A (ko) * 2014-03-12 2016-11-04 노파르티스 아게 Btk 억제제 및 akt 억제제를 포함하는 조합물
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
EP3122753A4 (en) * 2014-03-27 2017-11-29 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
CN105085529A (zh) * 2014-05-15 2015-11-25 广东东阳光药业有限公司 依鲁替尼新晶型及其制备方法
US20160008366A1 (en) * 2014-07-14 2016-01-14 Pharmacyclics Llc Btk inhibitors for the treatment of cns malignancies
KR20170042614A (ko) * 2014-08-01 2017-04-19 파마싸이클릭스 엘엘씨 Btk 저해제를 이용한 치료에 대한 dlbcl의 반응을 예측하기 위한 바이오마커
CN106999494A (zh) 2014-08-01 2017-08-01 药品循环有限公司 布鲁顿酪氨酸激酶的抑制剂
JP2017523206A (ja) 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
JP2017523207A (ja) * 2014-08-08 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用
EP3180343A1 (en) 2014-08-14 2017-06-21 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
US10059715B2 (en) 2014-10-01 2018-08-28 Ratiopharm Gmbh Acid addition salt of ibrutinib
WO2016079216A1 (en) 2014-11-20 2016-05-26 Sandoz Ag Physical forms of ibrutinib, a bruton's kinase inhibitor
DK3115365T3 (en) 2015-01-30 2018-05-28 Taiho Pharmaceutical Co Ltd HIS UNKNOWN SALT OF CONDENSED PYRIMIDIDE COMPOUND AND CRYSTALS THEREOF
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
EP3265092A4 (en) * 2015-03-03 2018-07-18 Dr. Reddy's Laboratories Ltd. Polymorphs of ibrutinib
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MX2017011990A (es) * 2015-03-20 2018-06-06 Crystal Pharmatech Co Ltd Metodo de preparacion de la forma a cristalina de pci-32765.
MA41828A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
JP6705833B2 (ja) * 2015-04-02 2020-06-03 ラティオファルム ゲー・エム・ベー・ハー イブルチニブとカルボン酸との共結晶
SI3892302T1 (sl) * 2015-04-06 2023-11-30 Janssen Pharmaceutica Nv Sestavki, ki vsebujejo ibrutinib
CN106153797B (zh) * 2015-04-20 2017-08-29 北京睿创康泰医药研究院有限公司 一种依鲁替尼及依鲁替尼制剂有关物质分析方法
CN106153798B (zh) * 2015-04-22 2017-08-29 北京睿创康泰医药研究院有限公司 一种用于分析依鲁替尼及依鲁替尼制剂有关物质的hplc方法以及这些杂质做参比标准的用途
WO2016207172A1 (en) * 2015-06-26 2016-12-29 Sandoz Gmbh Preparation of pure amorphous ibrutinib
CZ2015442A3 (cs) * 2015-06-26 2017-01-04 Zentiva, K.S. Ibrutinib hemisulfát
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
US11001585B2 (en) 2015-08-19 2021-05-11 Sun Pharmaceutical Industries Limited Crystalline forms of ibrutinib
HUE053638T2 (hu) * 2015-09-18 2021-07-28 Mycovia Pharmaceuticals Inc Eljárás gombaellenes vegyület elõállítására
TWI642671B (zh) * 2015-10-28 2018-12-01 台灣神隆股份有限公司 依魯替尼之製備方法及其中間體
ITUB20155616A1 (it) * 2015-11-16 2017-05-16 Laboratorio Chimico Int S P A Procedimento per la preparazione della forma amorfa dell?ibrutinib e nuova forma cristallina.
CN105294696A (zh) * 2015-11-19 2016-02-03 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
EP3384294B1 (en) 2015-12-04 2021-10-13 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
CN105622614B (zh) * 2015-12-18 2021-02-26 重庆医药工业研究院有限责任公司 一种依鲁替尼无定型物及其制备方法
CN106905320A (zh) * 2015-12-23 2017-06-30 杭州容立医药科技有限公司 一种适合药用的依鲁替尼及其制剂
CN114681462A (zh) * 2016-01-19 2022-07-01 詹森药业有限公司 包含btk抑制剂的配制品/组合物
WO2017125423A1 (en) * 2016-01-19 2017-07-27 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
CN106995445B (zh) * 2016-01-22 2021-08-03 山东新时代药业有限公司 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法
WO2017129087A1 (zh) * 2016-01-27 2017-08-03 江苏恒瑞医药股份有限公司 一种含有喹啉衍生物或其盐的药物组合物
US10626117B2 (en) 2016-02-01 2020-04-21 Natco Pharma Limited Process for the preparation of Ibrutinib
US10435409B2 (en) 2016-02-04 2019-10-08 Shilpa Medicare Limited Process for the preparation of ibrutinib
GB2558514A (en) * 2016-02-09 2018-07-18 Azad Pharmaceutical Ingredients Ag Process for the synthesis of stable amorphous ibrutinib
CN105646498A (zh) * 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型f及制备方法
CN107286163A (zh) * 2016-03-30 2017-10-24 上海星泰医药科技有限公司 一种依鲁替尼的新晶型及其制备方法
CZ2016196A3 (cs) 2016-04-06 2017-10-18 Zentiva, K.S. Pevné formy Ibrutinibu
CZ2016276A3 (cs) 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
EA201990140A1 (ru) * 2016-06-28 2019-07-31 Мехмет Невзат Писак Поверхностно-активные вещества для лечения инфекций кожи, вызываемых содержащими двухцепочечную днк вирусами семейств herpesviridae или papillomaviridae
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN106117214A (zh) * 2016-06-29 2016-11-16 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
US20200039981A1 (en) 2016-10-06 2020-02-06 Janssen Pharmaceutica Nv Processes and intermediates for preparing a btk inhibitor
US20190298772A1 (en) 2016-11-03 2019-10-03 Juno Therapeutics, Inc. Combination therapy of a t cell-based therapy and a btk inhibitor
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
CN111201438A (zh) 2017-06-02 2020-05-26 朱诺治疗学股份有限公司 与和细胞疗法相关的毒性有关的制品和方法
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
AU2018296476B2 (en) 2017-07-04 2023-11-02 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition and method for preparing same
EP3676403A1 (en) 2017-09-01 2020-07-08 Juno Therapeutics, Inc. Gene expression and assessment of risk of developing toxicity following cell therapy
WO2019058386A1 (en) 2017-09-19 2019-03-28 Cipla Limited COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING IMPROVED BIOAVAILABILITY
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company Novel forms of ibrutinib
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2019142207A1 (en) 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
EP3773591A4 (en) 2018-04-05 2021-12-22 Sumitomo Dainippon Pharma Oncology, Inc. AXL KINASE INHIBITORS AND THEIR USE
WO2019195827A1 (en) * 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
CN117959303A (zh) 2018-04-13 2024-05-03 住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
US20220009929A1 (en) 2018-05-02 2022-01-13 Cipla Limited Polymorphic forms of ibrutinib
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
RU2711106C2 (ru) * 2018-06-06 2020-01-15 Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" Кристаллическая μ-модификация 1-[(3R)-3-[4-амино-3-(4-фенокси-фенил)-1Н-пиразоло[3,4-d]пиримидин-1-ил]-1-пиперидил]-2-пропенил-1-она, способ её получения и фармацевтическая композиция на её основе
KR102844084B1 (ko) 2018-06-15 2025-08-07 얀센 파마슈티카 엔브이 이브루티닙을 포함하는 제형/조성물
JP2021527685A (ja) 2018-06-19 2021-10-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ １−（４−｛［６−アミノ−５−（４−フェノキシ−フェニル）−ピリミジン−４−イルアミノ］−メチル｝−４−フルオロ−ピペリジン−１−イル）−プロペノンの新規な結晶形態、その塩形態、および得るためのプロセス
CN108727387B (zh) * 2018-07-25 2021-03-16 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
CN110804058B (zh) * 2018-08-06 2022-11-11 鲁南制药集团股份有限公司 一种伊布替尼新晶型及其制备方法
CN111138436A (zh) * 2018-11-04 2020-05-12 鲁南制药集团股份有限公司 伊布替尼晶型a单晶及其制备方法
FI3886875T3 (fi) 2018-11-30 2024-07-23 Juno Therapeutics Inc Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
ES2986007T3 (es) 2018-11-30 2024-11-08 Juno Therapeutics Inc Métodos para la dosificación y el tratamiento de neoplasias malignas de linfocitos B en terapia celular adoptiva
KR20210102933A (ko) 2018-12-06 2021-08-20 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
BR112021010708A2 (pt) 2018-12-06 2021-08-24 Arthrosi Therapeutics, Inc. Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
MX2021010144A (es) * 2019-02-22 2021-09-14 Janssen Pharmaceutica Nv Formulaciones farmaceuticas.
EP4045051A1 (en) 2019-10-14 2022-08-24 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CN115398231A (zh) 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
CN113135917A (zh) * 2020-01-16 2021-07-20 北京赛思源生物医药技术有限公司 一种依鲁替尼的无定型物及其药用组合物
CN113214261A (zh) * 2020-01-21 2021-08-06 尚科生物医药（上海）有限公司 一种依鲁替尼晶型a的纯化方法
PH12022551787A1 (en) 2020-01-22 2024-02-12 Principia Biopharma Inc Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021207716A2 (en) * 2020-04-10 2021-10-14 Ohio State Innovation Foundation Methods and composition for treatment of covid-19 illness requiring hospitalization
TW202208345A (zh) * 2020-05-09 2022-03-01 美商亞文納營運公司 雙官能性化合物的製造方法、該雙官能性化合物的超純形式、及含彼之劑型
CN114099509B (zh) * 2020-08-26 2023-12-08 长庚大学 一种酪氨酸激酶抑制剂在制造用以治疗因炎性体激活所致相关疾病的药物中的用途
US20230320990A1 (en) 2020-08-28 2023-10-12 Synthon B.V. Pharmaceutical composition comprising ibrutinib
CU20230026A7 (es) * 2020-11-19 2024-01-10 Pliant Therapeutics Inc Formas cristalinas de inhibidor de integrina y sales de estas
EP4281454B1 (en) 2021-01-21 2025-03-05 Synthon B.V. Process for making ibrutinib
WO2022260667A1 (en) 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Oral dosage forms of ibrutinib
US11433072B1 (en) 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CA3258534A1 (en) * 2022-06-07 2023-12-14 Lantern Pharma Inc. CANCER TREATMENT USING COMBINATIONS OF ACYLFULVENS AND IBRUTINIB OR BORTÉZOMIB
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms
WO2025054271A2 (en) * 2023-09-06 2025-03-13 Foresee Pharmaceuticals Usa, Inc. Pharmaceutical composition with enhanced properties, method for preparation, and use thereof
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
CN121591740A (zh) * 2024-08-23 2026-03-03 成都泰立贝医药技术有限公司 一种依鲁替尼单月桂醇硫酸盐、制备方法、应用

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006596A (en) 1909-05-20 1911-10-24 Kansas City Feed Company Ltd Alfalfa-mill.
US1008594A (en) 1910-12-17 1911-11-14 Arthur Graham France Advertising device.
US1010536A (en) 1911-05-01 1911-12-05 John B Turbeville Cook-stove.
US1010654A (en) 1911-06-20 1911-12-05 Albert F Madden Cyclometer.
JPS5841998B2 (ja) 1980-07-28 1983-09-16 株式会社日立製作所 核燃料掴み装置
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3303707A1 (de) 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
CA2122479C (en) 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
ATE242245T1 (de) 1997-03-19 2003-06-15 Basf Ag Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
DE69808670T2 (de) 1997-12-31 2003-07-03 Choongwae Pharma Corp., Seoul/Soul Herstellungsverfahren und zusammensetzung einer oralen zubereitung von itraconazol
CA2328962A1 (en) 1998-04-17 1999-10-28 Parker Hughes Institute Btk inhibitors and methods for their identification and use
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
IL148718A0 (en) 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
ES2225231T3 (es) 1999-10-06 2005-03-16 Boehringer Ingelheim Pharmaceuticals Inc. Compuestos heterociclicos, utiles como inhibidores de tirosina quinasas.
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
CA2390857A1 (en) 1999-11-30 2001-06-14 Fatih M. Uckun Inhibitors of collagen-induced platelet aggregation
IL150059A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
GB0108903D0 (en) 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
CA2426508A1 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
JP2004514732A (ja) 2000-12-06 2004-05-20 ファルマシア・コーポレーション 迅速に分散する医薬組成物
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
EP1463742A4 (en) 2001-06-21 2006-05-10 Ariad Pharma Inc NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
CN1523991A (zh) 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
IL161409A0 (en) 2001-11-21 2004-09-27 Sunesis Pharmaceuticals Inc Methods for ligand discovery
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
UA83509C2 (en) 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
US20050153990A1 (en) 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
PL1701698T3 (pl) 2004-01-08 2008-03-31 Wyeth Corp Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779
EP1716151A1 (en) 2004-01-26 2006-11-02 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
ITMI20041314A1 (it) 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
AU2005290028A1 (en) 2004-09-28 2006-04-06 Janssen Pharmaceutica, N.V. Substituted dipiperdine CCR2 antagonists
EP1812442A2 (en) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
MX2007011041A (es) 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
BRPI0610278A2 (pt) 2005-05-13 2010-06-08 Irm Llc compostos e composições como inibidores de proteìna cinase
NZ563692A (en) 2005-05-23 2011-04-29 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
PL2395004T3 (pl) 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
EP1934185A1 (en) 2005-08-12 2008-06-25 Synta Pharmaceuticals Corporation Pyrazole compounds that modulate hsp90 activity
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
US20080261975A1 (en) 2005-11-12 2008-10-23 Joerg Martin Bentzien Tec Kinase Inhibitors
RU2008133161A (ru) 2006-01-13 2010-02-20 Фармасайкликс, Инк. (Us) Ингибиторы тирозин киназ и их применение
JP2009525468A (ja) 2006-01-30 2009-07-09 ザ・スクリプス・リサーチ・インステイチユート 循環腫瘍細胞の検出方法および哺乳類対象における癌の診断方法
US20070218138A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US8604031B2 (en) 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
FI20080352A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
JP2010516704A (ja) 2007-01-22 2010-05-20 ノババックス，インコーポレイテッド 摂食／絶食による変動性を低減し、かつ経口バイオアベイラビリティーを改善するための難水溶性薬物の多相医薬製剤
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
DK2142529T3 (da) 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
JP2010535232A (ja) 2007-07-30 2010-11-18 アルディア バイオサイエンス，インク． Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
EP2214486A4 (en) 2007-10-19 2011-03-09 Avila Therapeutics Inc HETEROARYL COMPOUNDS AND ITS USES
EP2205564B1 (en) 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
CA2720744A1 (en) 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
WO2009129246A2 (en) 2008-04-14 2009-10-22 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
CN105362277A (zh) 2008-07-16 2016-03-02 药品循环有限公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
ES2620442T3 (es) 2008-07-29 2017-06-28 Frontier Scientific, Inc. Uso de derivados de tetraquis(N-alquilpiridinio)-porfirina para la destrucción de microbios o la prevención de su crecimiento
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
IN2012DN02534A (es) 2009-09-16 2015-08-28 Avila Therapeutics Inc
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
WO2011152351A1 (ja) 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
MY160734A (en) 2010-08-10 2017-03-15 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
CA2807687C (en) 2010-08-12 2019-01-08 Boehringer Ingelheim International Gmbh 6-cycloalkyl-1, 5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
US8541391B2 (en) 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
US8962831B2 (en) 2011-05-17 2015-02-24 Principia Biopharma Inc. Tyrosine kinase inhibitors
JP2014523445A (ja) 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP3181128B1 (en) 2012-01-13 2023-03-08 XSpray Pharma AB (publ) Nilotinib pharmaceuticalcomposition
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
JP5514256B2 (ja) 2012-05-18 2014-06-04 株式会社東芝 磁気記憶素子及びその製造方法
EA201492082A1 (ru) * 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
DK2861599T3 (da) 2012-06-18 2020-03-02 Principia Biopharma Inc Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN103121999A (zh) 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
MX2015006168A (es) 2012-11-15 2015-08-10 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas.
WO2014168975A1 (en) 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy
SG10201709926VA (en) 2013-05-30 2017-12-28 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20160067241A1 (en) * 2013-06-13 2016-03-10 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
TWI649081B (zh) 2013-08-02 2019-02-01 製藥公司 治療固態腫瘤之方法
ES2709509T3 (es) 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
WO2015034478A1 (en) 2013-09-04 2015-03-12 Halliburton Energy Services, Inc. Scale-inhibiting cocrystals for treatment of a subterranean formation
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
CN104447701B (zh) 2013-09-17 2019-03-22 广东东阳光药业有限公司 吡唑类衍生物及其用途
EP3060218A4 (en) 2013-10-25 2017-07-19 Pharmacyclics LLC Methods of treating and preventing graft versus host disease
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
WO2015071432A1 (en) 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
CA2932255C (en) 2013-12-02 2023-10-10 Pharmacyclics Llc Methods of treating and preventing alloantibody driven chronic graft versus host disease
EP3077384B1 (en) 2013-12-05 2017-09-06 F. Hoffmann-La Roche AG Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
WO2015095772A2 (en) 2013-12-20 2015-06-25 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
CN105949197A (zh) 2014-01-29 2016-09-21 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
US20150231077A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
US20150267752A1 (en) 2014-03-19 2015-09-24 Roller Bearing Company Of America, Inc. Bearing outer race having a radially inwardly biased seal
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
EP3122753A4 (en) 2014-03-27 2017-11-29 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
WO2015149056A1 (en) 2014-03-28 2015-10-01 Board Of Regents, The University Of Texas System Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury
CN105085529A (zh) 2014-05-15 2015-11-25 广东东阳光药业有限公司 依鲁替尼新晶型及其制备方法
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
US20150110871A1 (en) 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions
US20160008777A1 (en) 2014-07-09 2016-01-14 Novotec Consulting Inc. Pharmaceutical compounding kit
PT107846B (pt) 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
WO2016020697A1 (en) 2014-08-06 2016-02-11 Cipla Limited Pharmaceutical compositions of polymeric nanoparticles
JP2017523206A (ja) 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
EP3180343A1 (en) 2014-08-14 2017-06-21 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
US10059715B2 (en) 2014-10-01 2018-08-28 Ratiopharm Gmbh Acid addition salt of ibrutinib
CN104523695A (zh) 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN105640961A (zh) 2014-11-18 2016-06-08 山东瑞禾医药科技有限公司 一种含依鲁替尼的药物组合物
WO2016079216A1 (en) 2014-11-20 2016-05-26 Sandoz Ag Physical forms of ibrutinib, a bruton's kinase inhibitor
US20150224060A1 (en) 2015-01-03 2015-08-13 David Wong Gastric retentive tablet compositions
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
EP3265092A4 (en) 2015-03-03 2018-07-18 Dr. Reddy's Laboratories Ltd. Polymorphs of ibrutinib
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
JP6705833B2 (ja) 2015-04-02 2020-06-03 ラティオファルム ゲー・エム・ベー・ハー イブルチニブとカルボン酸との共結晶
SI3892302T1 (sl) 2015-04-06 2023-11-30 Janssen Pharmaceutica Nv Sestavki, ki vsebujejo ibrutinib
CN105294696A (zh) 2015-11-19 2016-02-03 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
CN105440040B (zh) 2015-12-23 2018-03-13 浙江京新药业股份有限公司 依鲁替尼的纯化方法
CN114681462A (zh) 2016-01-19 2022-07-01 詹森药业有限公司 包含btk抑制剂的配制品/组合物
WO2017125423A1 (en) 2016-01-19 2017-07-27 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
CN105646498A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型f及制备方法
CN105646484A (zh) 2016-03-01 2016-06-08 孙霖 晶型b及制备方法
CN105646499A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型g及制备方法
CN106619643A (zh) 2016-11-11 2017-05-10 上海雅本化学有限公司 一种含依鲁替尼的药物组合物

Also Published As

Publication number Publication date
CA2875986A1 (en) 2013-12-12
JP2023162162A (ja) 2023-11-08
JP6937086B6 (ja) 2021-10-27
SG10202101389TA (en) 2021-03-30
US10106548B2 (en) 2018-10-23
CA2991994C (en) 2022-06-28
WO2013184572A1 (en) 2013-12-12
JP6236071B2 (ja) 2017-11-22
TN2014000492A1 (en) 2016-03-30
HK1208803A1 (en) 2016-03-18
US20220112196A1 (en) 2022-04-14
MA41654B2 (fr) 2020-12-31
US20130338172A1 (en) 2013-12-19
UY39740A (es) 2022-06-30
UA114421C2 (uk) 2017-06-12
US20180179214A1 (en) 2018-06-28
BR112014030424A8 (pt) 2017-07-11
US10961251B1 (en) 2021-03-30
US20180319805A1 (en) 2018-11-08
JP2015518885A (ja) 2015-07-06
AU2020239751A1 (en) 2020-10-22
KR20230170108A (ko) 2023-12-18
JP2018012710A (ja) 2018-01-25
MY187999A (en) 2021-11-08
AR092844A1 (es) 2015-05-06
AU2018211216B2 (en) 2020-06-25
MX2014014848A (es) 2015-07-06
KR20220093389A (ko) 2022-07-05
AU2013271918B2 (en) 2016-08-04
US20260062417A1 (en) 2026-03-05
CA3218491A1 (en) 2013-12-12
US20150158871A1 (en) 2015-06-11
PE20150174A1 (es) 2015-02-12
US20180170940A1 (en) 2018-06-21
IL235894A0 (en) 2015-01-29
MX2021012478A (es) 2021-11-12
US10065968B2 (en) 2018-09-04
US20170100404A1 (en) 2017-04-13
PE20241581A1 (es) 2024-08-01
ZA202502152B (en) 2025-08-27
BR112014030424A2 (pt) 2017-06-27
MY194911A (en) 2022-12-22
US9725455B1 (en) 2017-08-08
NZ713828A (en) 2017-05-26
JP2025176017A (ja) 2025-12-03
US9713617B2 (en) 2017-07-25
KR20200017549A (ko) 2020-02-18
JP6937086B2 (ja) 2021-09-22
US20140336203A1 (en) 2014-11-13
US20180179215A1 (en) 2018-06-28
ECSP14033163A (es) 2015-09-30
CA3015208A1 (en) 2013-12-12
TWI662963B (zh) 2019-06-21
US20210070759A1 (en) 2021-03-11
UA126959C2 (uk) 2023-03-01
US20170334921A1 (en) 2017-11-23
IL254739A0 (en) 2017-11-30
US20200148691A1 (en) 2020-05-14
NZ737725A (en) 2019-06-28
UY34848A (es) 2013-10-31
TWI662964B (zh) 2019-06-21
NZ731932A (en) 2018-09-28
TW201811334A (zh) 2018-04-01
AU2016250445B2 (en) 2018-07-26
AU2023200435A1 (en) 2023-03-02
CA2875986C (en) 2020-06-09
US9540382B2 (en) 2017-01-10
CL2014003306A1 (es) 2015-04-17
AU2018211216A1 (en) 2018-08-16
AU2020239751B2 (en) 2022-10-27
EP2854859A1 (en) 2015-04-08
PH12014502681A1 (en) 2015-01-26
CN110354132A (zh) 2019-10-22
MA41654A1 (fr) 2018-07-31
US10266540B2 (en) 2019-04-23
US20190248799A1 (en) 2019-08-15
SG11201408067YA (en) 2015-01-29
KR20150015021A (ko) 2015-02-09
ZA202303227B (en) 2024-01-31
CO7240408A2 (es) 2015-04-17
TW201402122A (zh) 2014-01-16
US20180319806A1 (en) 2018-11-08
ZA202105175B (en) 2022-07-27
EP2854859A4 (en) 2016-01-13
US20180362535A1 (en) 2018-12-20
AU2018211201A1 (en) 2018-08-16
CL2017000371A1 (es) 2017-10-30
ZA202105174B (en) 2022-07-27
CA2991994A1 (en) 2013-12-12
CR20140558A (es) 2015-03-13
AU2013271918A1 (en) 2015-01-22
AU2025205154A1 (en) 2025-07-24
EA201492082A1 (ru) 2015-03-31
TWI653041B (zh) 2019-03-11
PH12020500028A1 (en) 2022-02-21
PE20190390A1 (es) 2019-03-13
DOP2022000096A (es) 2022-07-15
IL282367A (en) 2021-06-30
KR20250151610A (ko) 2025-10-21
DOP2014000274A (es) 2015-03-31
US20180362536A1 (en) 2018-12-20
JP2020015744A (ja) 2020-01-30
JO3754B1 (ar) 2021-01-31
US9828383B1 (en) 2017-11-28
US20180155352A1 (en) 2018-06-07
US20190248798A1 (en) 2019-08-15
US10294231B2 (en) 2019-05-21
JP2019203008A (ja) 2019-11-28
MX387669B (es) 2025-03-18
CL2017003496A1 (es) 2018-06-22
PH12021552282A1 (en) 2023-02-20
AR118108A2 (es) 2021-09-15
US20200223856A1 (en) 2020-07-16
IL235894B (en) 2020-03-31
US10125140B1 (en) 2018-11-13
US20180327415A1 (en) 2018-11-15
US9296753B2 (en) 2016-03-29
US20240409545A1 (en) 2024-12-12
DOP2017000152A (es) 2017-07-31
AU2023200435B2 (en) 2025-04-10
JP2025186225A (ja) 2025-12-23
GT201400281A (es) 2019-08-12
IL315394A (en) 2024-11-01
NZ702548A (en) 2015-11-27
CA3015208C (en) 2024-01-02
TW201906612A (zh) 2019-02-16
JP2021183617A (ja) 2021-12-02
JP2021193095A (ja) 2021-12-23
US20170305919A1 (en) 2017-10-26
US20200231595A1 (en) 2020-07-23
AU2016250445A1 (en) 2016-11-17
AU2013271918A8 (en) 2015-02-26
KR20210033067A (ko) 2021-03-25
CN104736178A (zh) 2015-06-24
KR20170091785A (ko) 2017-08-09
AU2013271918C1 (en) 2017-02-09
JOP20200222A1 (ar) 2022-10-30
US20210032258A1 (en) 2021-02-04
US20170226112A1 (en) 2017-08-10
KR20190040370A (ko) 2019-04-17
AU2018211201B2 (en) 2020-06-25
US10294232B2 (en) 2019-05-21
US10752634B2 (en) 2020-08-25
JP2018048182A (ja) 2018-03-29
ECSP19015794A (es) 2019-03-29
EP2854859B1 (en) 2026-02-25
MA37711A1 (fr) 2017-05-31
US20180362534A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
DOP2022000096A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
MX2017011270A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
CO6630162A2 (es) Derivados del ácido 1-amino -2-ciclopropiletilboronico
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
PE20151070A1 (es) Inhibidores de la tirosina - quinasa de bruton
PE20151788A1 (es) Inhibidores de bromodominios tetraciclicos
BR112012020693A2 (pt) derivados de ciclobutano e metilciclobutano como inibidores de janus quinase
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
MX2014010589A (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
ECSP10010389A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
SV2011003839A (es) Agentes antifungicos

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: PHARMACYCLICS LLC

HC Change of company name or juridical status

Owner name: PHARMACYCLICS LLC

FG Grant or registration